A gene mutation that is believed to have safeguarded some people in 14th century Europe from the bubonic plague today may be protecting HIV patients co-infected with hepatitis C from potentially fatal liver scarring, says a University of Cincinnati (UC) College of Medicine physician-scientist.
Patients who experience disturbances in sleep, mobility, nutrition or mood while admitted in hospital may be more likely to be readmitted within 30 days after discharge, finds a new study co-led by St. Michael's Hospital and the University Health Network (UHN) in Canada.
A team of researchers led by Jonathan Stamler, MD, of Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center, has discovered a pathway for enhancing the self-repair efforts of injured kidneys The finding may pave the way for new drugs to stop or even reverse the progression of serious kidney disease in humans -- and other potentially lethal conditions of the heart, liver, and brain as well.
Targeted testing to reach those most at-risk of infection is an essential element of any strategy to eliminate viral hepatitis and HIV across the countries in the European Union and European Economic Area (EU/EEA). To mark European Testing Week from Nov. 23 to 30, 2018, ECDC publishes its new Guidance on integrated viral hepatitis and HIV testing which provides options and ideas based on the latest scientific evidence for national or local hepatitis B, C and HIV testing guidelines and programmes.
Infant gut microbes altered by their mother's obesity can cause inflammation and other major changes within the baby, increasing the risk of obesity and non-alcoholic fatty liver disease later in life, according to researchers at the University of Colorado Anschutz Medical Campus.
People living in colder regions with less sunlight consume more alcohol and experience more alcoholic liver disease.
National Institutes of Health scientists and their collaborators found that hepatitis B virus (HBV)-associated acute liver failure (ALF) -- a rare condition that can turn fatal within days without liver transplantation -- results from an uncommon encounter between a highly mutated HBV variant and an unusual immune response in the patient's liver that is mainly sustained by antibody-producing B cells.
A research team based in Japan led by Kanazawa University has demonstrated the effect of osteopontin on hepatitis C virus replication and interferon signaling in cancer stem cells. Their research sheds light on a novel therapeutic target for treating hepatocellular carcinoma.
Children's Hospital Colorado (Children's Colorado) pediatric gastroenterologist, Michael Narkewicz, MD, recently shared results of the Prospective Study of Ultrasound to Predict Hepatic Cirrhosis in Cystic Fibrosis (PUSH), which sought to determine if liver ultrasounds could identify children and adolescents with cystic fibrosis who are at greater risk of developing advanced liver disease.
Hepatitis C drugs cure more than 90 percent of patients, but can cost more than $50,000 per patient. Findings from a Loyola University Chicago study could lead to significant cost savings. In 50 percent of patients, the standard 12-week treatment regimen could be shortened to as little as six weeks without compromising efficacy, the study found.